Skip to main content
All lobbying filings

DLA PIPER LLP (US)

Lobbying for BIOGEN, INC. · Biotechnology company.

 Filing 2nd Quarter - Report
Reporting period
2nd Quarter 2025
Apr 1 - June 30 · Posted Jul 21, 2025
Income
$60,000.00
What the client paid this registrant for the period.
Client based in
District of Columbia

Official filing document

 Government bodies contacted 4
  • Centers For Medicare and Medicaid Services (CMS)
  • Health & Human Services, Dept of (HHS)
  • HOUSE OF REPRESENTATIVES
  • SENATE

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when.

 Bills named in this filing 2
  • HR 1492
    To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic can…
  • S 832
    EPIC Act of 2025
 Lobbying activity 6
Pharmacy

Issues relating to drug pricing policy. Pharmacy benefit manager legislation related to patient access to therapies. H.R. 1492/S. 832, EPIC Act.

Copyright/Patent/Trademark

Intellectual property protections and enforcement. Biopharmaceutical patent policy.

Health Issues

Issues related to rare diseases including Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), Lou Gehrig's Disease. Drug pricing supply chain. Screening and diagnosis. Patient affordability and access issues, including copay cards, copay accumulators, copay maximizers, coverage issues. Orphan Drug Act. Issues related to the FDA including PDUFA, drug reviews, approval pathways, and clinical trials. Drug pricing. Supply chain issues and gene therapy. Policies related to value based arrangements and implementation of Inflation Reduction Act of 2022.

Medical/Disease Research/Clinical Labs

Issues related to rare disease and treatment. Pricing policy. Issues related to the Medicaid 340B program. Public policy around patients' access and affordability. Alzheimer's disease. Issues related to Medicare Part B and D.

Taxation/Internal Revenue Code

Issues related to tax reform.

Trade (domestic/foreign)

Trade-related public policy around tariffs and intellectual property.

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem